CoChat

Exploiting convergent phenotypes to derive a pan-cancer cisplatin response gene expression signature

Open access
Scarborough, Jessica A., Eschrich, Steven A., Torres-Roca, Javier, Dhawan, Andrew, Scott, Jacob G. · 2023 · npj Precision Oncology

Published version of a preprint

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index; 24 of the 34 sources its claims cite were checked for support.

Abstract

Precision medicine offers remarkable potential for the treatment of cancer, but is largely focused on tumors that harbor actionable mutations. Gene expression signatures can expand the scope of precision medicine by predicting response to traditional (cytotoxic) chemotherapy agents without relying on changes in mutational status. We present a new signature extraction method, inspired by the principle of convergent phenotypes, which states that tumors with disparate genetic backgrounds may evolve similar phenotypes independently. This evolutionary-informed method can be utilized to produce consensus signatures predictive of response to over 200 chemotherapeutic drugs found in the Genomics of Drug Sensitivity in Cancer (GDSC) Database. Here, we demonstrate its use by extracting the Cisplatin Response Signature (CisSig). We show that this signature can predict cisplatin response within carcinoma-based cell lines from the GDSC database, and expression of the signatures aligns with clinical trends seen in independent datasets of tumor samples from The Cancer Genome Atlas (TCGA) and Total Cancer Care (TCC) database. Finally, we demonstrate preliminary validation of CisSig for use in muscle-invasive bladder cancer, predicting overall survival in a small cohort of patients who undergo cisplatin-containing chemotherapy. This methodology can be used to produce robust signatures that, with further clinical validation, may be used for the prediction of traditional chemotherapeutic response, dramatically increasing the reach of personalized medicine in cancer.

Overview

CoChat Summary

## TL;DR

The paper derives CisSig, a 19-gene cisplatin response expression signature, by combining differential expression in 429 epithelial cancer cell lines from GDSC with co-expression filtering in TCGA tumor/normal data. CisSig predicts cisplatin sensitivity in GDSC, aligns with cisplatin use patterns across TCGA and Total Cancer Care, and shows preliminary survival stratification in two muscle-invasive bladder cancer cohorts.

## Key findings

  • CisSig was derived from 429 epithelial-based cancer cell lines in GDSC; the authors used five 20% data partitions (each with 343 or 344 cell lines) to find genes consistent across folds.
  • In GDSC, the median CisSig score was higher in cisplatin-sensitive than resistant cell lines; for the “Cell Line Persistence Curve,” the median IC50 was 3.98 log2(µM) in the high-CisSig cohort versus 7.93 log2(µM) in the low-CisSig cohort.
  • CisSig was not strongly associated with common DNA damage response mutation status: among 16 genes examined, only PTEN showed a significant relationship with CisSig score after multiple-testing correction (p = 0.042).
  • Disease-site ranking by CisSig was concordant across datasets: Spearman’s r was 0.78 for GDSC vs TCGA, 0.92 for GDSC vs TCC, and 0.93 for TCGA vs TCC; higher CisSig generally aligned with disease sites where cisplatin appears in NCCN guidelines.
  • In MIBC, a CisSig-trained Cox model separated patients receiving cisplatin-containing chemotherapy into worse- vs better-survival groups, but the paper describes this as preliminary validation in a small cohort.

## Methods

  • The signature was built from GDSC microarray expression and cisplatin response data, using differential expression between the top and bottom 20% of IC50 responders with SAM, limma, and multtest, then intersecting genes upregulated in sensitive lines across all three methods.
  • The seed genes were refined with co-expression analysis in TCGA epithelial tumor/normal RNA-seq data; genes in the top 5% of affinity scores contributed to connectivity, and the final CisSig included genes present in at least 3 of 5 partitions.
  • Performance was tested with five-fold cross-validation in GDSC using simple and penalized regression, SVM, random forest, and survival-style “cell line persistence” analyses; external checks used TCGA, TCC, and two MIBC datasets.

## Limitations

  • The authors state that a single tumor sample may not capture intratumoral heterogeneity relevant to drug response.
  • They state that although the signature was designed for pan-cancer epithelial tumors, clinical validation must occur within individual disease sites, and site-specific trimming may be needed.
  • They explicitly note that the MIBC validation is preliminary because the sample sizes were relatively small, and that complete validation requires additional samples.
  • Evident from the text: the clinical survival analysis is limited by the fact that the authors could not always know which patients actually received cisplatin in external datasets, so some validation is based on treatment-assigned subsets and guideline concordance rather than direct, uniformly annotated response data.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41698-023-00375-y

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Visual representation of convergent evolution in animals and convergent phenotypes in tumors. a Birds and bats are genomically disparate, but both have individually evolved the ability to fly. b Two tumors may evolve cisplatin resistance independently, despite being genomically distinct from one another. Created with BioRender.com.
Fig. 1 Visual representation of convergent evolution in animals and convergent phenotypes in tumors. a Birds and bats are genomically disparate, but both have individually evolved the ability to fly. b Two tumors may evolve cisplatin resistance independently, despite being genomically distinct from one another. Created with BioRender.com.CC BY · PubMed Central
Fig. 2 Schematic representation of CisSig derivation. a Description of the epithelial-origin subset of the Genomics of Drug Discovery in Cancer (GDSC) dataset (denoted with the pill icon in future figures). These data include 429 epithelial-based cancer cell lines, with drug response measurements to over 200 drugs and gene expression characterization via microarray. b Pipeline for extracting connectivity seeds. First, differential gene expression analysis between the top and bottom 20% of cisplatin responders found genes with significantly increased expression in a state of cisplatin sensitivity. These differentially expressed genes became “seed genes” in a co-expression network built using gene expression from clinical samples of epithelial-based tumors and tissue in The Cancer Genome Atlas (TCGA). Seed genes that were highly co-expressed with each other were denoted as “connectivity genes.” c Schematic of data partitioning, where GDSC epithelial-based cancer cell lines from (a) are split into 5 folds. Each fold underwent the pipeline in (b). Genes found in at least 3 of the 5 connectivity gene sets were included in the final signature, CisSig. Created with BioRender.com.
Fig. 2 Schematic representation of CisSig derivation. a Description of the epithelial-origin subset of the Genomics of Drug Discovery in Cancer (GDSC) dataset (denoted with the pill icon in future figures). These data include 429 epithelial-based cancer cell lines, with drug response measurements to over 200 drugs and gene expression characterization via microarray. b Pipeline for extracting connectivity seeds. First, differential gene expression analysis between the top and bottom 20% of cisplatin responders found genes with significantly increased expression in a state of cisplatin sensitivity. These differentially expressed genes became “seed genes” in a co-expression network built using gene expression from clinical samples of epithelial-based tumors and tissue in The Cancer Genome Atlas (TCGA). Seed genes that were highly co-expressed with each other were denoted as “connectivity genes.” c Schematic of data partitioning, where GDSC epithelial-based cancer cell lines from (a) are split into 5 folds. Each fold underwent the pipeline in (b). Genes found in at least 3 of the 5 connectivity gene sets were included in the final signature, CisSig. Created with BioRender.com.CC BY · PubMed Central
Fig. 3 Visualization of CisSig expression within GDSC dataset. a An unclustered heatmap showing gene expression of the CisSig genes (rows) in cell lines (columns) from the top and bottom quintiles of cisplatin IC50. Color of the heatmap represents the Z-score of gene expression, normalized to each gene. Cell lines denoted as sensitive (right, yellow bar) tend to display higher expression of CisSig genes than cell lines denoted as resistant (left, green bar). Z-scores above 2.5 are denoted as 2.5, and Z-scores below −2.5 are denoted as −2.5. b Violin plots comparing the distribution of CisSig scores between the cell lines in the highest and lowest quintile of cisplatin IC50. A Wilcoxon rank-sum test found that the median CisSig scores between these two cohorts was significantly different (p < 0.0001). c Comparison of the distribution of cisplatin IC50 between cell lines in the highest and lowest quintile of CisSig score. Y-axis represents the proportion of the cohort with a cisplatin IC50 greater than the cisplatin concentration on the X-axis. A log-rank test between the two cohorts demonstrates significantly different drug response between the two cohorts (p < 0.0001). d Null distribution of hazard ratio using 1000 random gene signatures with the same length as CisSig and the model described in (c). CisSig’s performance is compared to the 95% confidence interval of the null distribution, where each signature’s performance (CisSig and nulls) is represented by the hazard ratio between two cohorts separated by the signature score. Created with BioRender.com.
Fig. 3 Visualization of CisSig expression within GDSC dataset. a An unclustered heatmap showing gene expression of the CisSig genes (rows) in cell lines (columns) from the top and bottom quintiles of cisplatin IC50. Color of the heatmap represents the Z-score of gene expression, normalized to each gene. Cell lines denoted as sensitive (right, yellow bar) tend to display higher expression of CisSig genes than cell lines denoted as resistant (left, green bar). Z-scores above 2.5 are denoted as 2.5, and Z-scores below −2.5 are denoted as −2.5. b Violin plots comparing the distribution of CisSig scores between the cell lines in the highest and lowest quintile of cisplatin IC50. A Wilcoxon rank-sum test found that the median CisSig scores between these two cohorts was significantly different (p < 0.0001). c Comparison of the distribution of cisplatin IC50 between cell lines in the highest and lowest quintile of CisSig score. Y-axis represents the proportion of the cohort with a cisplatin IC50 greater than the cisplatin concentration on the X-axis. A log-rank test between the two cohorts demonstrates significantly different drug response between the two cohorts (p < 0.0001). d Null distribution of hazard ratio using 1000 random gene signatures with the same length as CisSig and the model described in (c). CisSig’s performance is compared to the 95% confidence interval of the null distribution, where each signature’s performance (CisSig and nulls) is represented by the hazard ratio between two cohorts separated by the signature score. Created with BioRender.com.CC BY · PubMed Central
Fig. 4 CisSig predicts IC50 using a variety of modeling techniques in the GDSC dataset. a Scatterplot of the actual vs. predicted IC50 using CisSig score to predict IC50 with linear regression. Plot shows the best performing fold (measured by Spearman’s rho) from 5-fold cross validation. b Null distribution of the performance metric from (a) (Spearman’s rho), built using 1000 random gene signatures to predict IC50 as described in (a). As with CisSig, the metric of the best performing fold is used to represent each null signature. The median of the null distribution and the cutoff for the 95th percentile of the null distribution are represented by the solid and dashed gray line, respectively. CisSig’s performance, red solid line, outperforms at least 95% of the null distribution. c–d Violin plots containing the null distribution of performance metrics for 11 modeling methods, split into regression (continuous outcome) and classification (binary outcome) methods, respectively. Each distribution was created as discussed in a, b, where CisSig’s performance is compared to the performance of 1000 random gene signatures of the same length. For each violin, a shaded gray bar represents the top 5% of each null distribution and CisSig’s performance is shown with a red dot. The modeling methods, including input and output, are described in Table 2. Created with BioRender.com.
Fig. 4 CisSig predicts IC50 using a variety of modeling techniques in the GDSC dataset. a Scatterplot of the actual vs. predicted IC50 using CisSig score to predict IC50 with linear regression. Plot shows the best performing fold (measured by Spearman’s rho) from 5-fold cross validation. b Null distribution of the performance metric from (a) (Spearman’s rho), built using 1000 random gene signatures to predict IC50 as described in (a). As with CisSig, the metric of the best performing fold is used to represent each null signature. The median of the null distribution and the cutoff for the 95th percentile of the null distribution are represented by the solid and dashed gray line, respectively. CisSig’s performance, red solid line, outperforms at least 95% of the null distribution. c–d Violin plots containing the null distribution of performance metrics for 11 modeling methods, split into regression (continuous outcome) and classification (binary outcome) methods, respectively. Each distribution was created as discussed in a, b, where CisSig’s performance is compared to the performance of 1000 random gene signatures of the same length. For each violin, a shaded gray bar represents the top 5% of each null distribution and CisSig’s performance is shown with a red dot. The modeling methods, including input and output, are described in Table 2. Created with BioRender.com.CC BY · PubMed Central
Fig. 5 Cancer subtypes with greater CisSig expression tend to have cisplatin included in standard of care guidelines. Cancer subtypes are ranked by median CisSig Score in three datasets, GDSC (left), TCGA (middle), and TCC (right). The color of each violin plot represents the rank of the cancer subtype. The ranks of intersecting subtypes between each dataset are compared with Spearman’s rank correlation, reported with correlation ρ and p-value. Rank correlation ρ between GDSC and TCGA and GDSC and TCC datasets is 0.78 (p = 0.0002) and 0.92 (p < 0.0001), respectively. Rank correlation r between TCGA and TCC datasets is 0.93 (p < 0.0001). Violin plots display the distribution of CisSig scores for each cancer subtype. Within each violin, a boxplot denotes median signature score for each subtype (middle horizontal line) and 25th/75th percentile for signature scores (box edges). Numbers to the left of each violin plot represent sample size included in each cancer subtype. For disease sites labeled as using cisplatin in select circumstances, notes about these circumstances are included in Supplementary Table 8. Created with BioRender.com.
Fig. 5 Cancer subtypes with greater CisSig expression tend to have cisplatin included in standard of care guidelines. Cancer subtypes are ranked by median CisSig Score in three datasets, GDSC (left), TCGA (middle), and TCC (right). The color of each violin plot represents the rank of the cancer subtype. The ranks of intersecting subtypes between each dataset are compared with Spearman’s rank correlation, reported with correlation ρ and p-value. Rank correlation ρ between GDSC and TCGA and GDSC and TCC datasets is 0.78 (p = 0.0002) and 0.92 (p < 0.0001), respectively. Rank correlation r between TCGA and TCC datasets is 0.93 (p < 0.0001). Violin plots display the distribution of CisSig scores for each cancer subtype. Within each violin, a boxplot denotes median signature score for each subtype (middle horizontal line) and 25th/75th percentile for signature scores (box edges). Numbers to the left of each violin plot represent sample size included in each cancer subtype. For disease sites labeled as using cisplatin in select circumstances, notes about these circumstances are included in Supplementary Table 8. Created with BioRender.com.CC BY · PubMed Central
Fig. 6 CisSig-trained model is predictive in patients who have received cisplatin, but lacks signal in patients who have not received cisplatin. a Schematic description of model training and testing, where a model is trained using patients who did receive cisplatin-containing treatment from Dataset A. Testing of the trained model is done using patients from the Dataset A who did not receive cisplatin-containing treatment and patients from the Dataset B who did receive cisplatin-containing treatment. b Test samples that did receive cisplatin-containing treatment are separated into groups of “high” and “low risk” based on the model’s predictions using a median cutoff. Kaplan–Meier curves show a significant separation between the two groups. c The same analysis shown in (b), using an optimal cutpoint (determined by chi-square statistic) instead of median to separate the cohorts. d, e The same analyses shown in (b, c), separating the groups into “high”, “middle”, and “low risk” groups using tertiles and the optimal two cutpoints, respectively. f, g The same analyses shown in (b) and (d), using samples from Dataset A that did not receive cisplatin-containing treatment, demonstrating no significant separation between the two groups. Created with BioRender.com.
Fig. 6 CisSig-trained model is predictive in patients who have received cisplatin, but lacks signal in patients who have not received cisplatin. a Schematic description of model training and testing, where a model is trained using patients who did receive cisplatin-containing treatment from Dataset A. Testing of the trained model is done using patients from the Dataset A who did not receive cisplatin-containing treatment and patients from the Dataset B who did receive cisplatin-containing treatment. b Test samples that did receive cisplatin-containing treatment are separated into groups of “high” and “low risk” based on the model’s predictions using a median cutoff. Kaplan–Meier curves show a significant separation between the two groups. c The same analysis shown in (b), using an optimal cutpoint (determined by chi-square statistic) instead of median to separate the cohorts. d, e The same analyses shown in (b, c), separating the groups into “high”, “middle”, and “low risk” groups using tertiles and the optimal two cutpoints, respectively. f, g The same analyses shown in (b) and (d), using samples from Dataset A that did not receive cisplatin-containing treatment, demonstrating no significant separation between the two groups. Created with BioRender.com.CC BY · PubMed Central

Verification

Claims the paper makes

11 Valid · 2 Not valid · 3 Not checked · 62 Own results and interpretations

42 more claims

Create a free account to see all 78 claims and to verify the 2 references still open.

See all claims — free account
  • Probably not a substantial claim. 23
  • It may state two separate claims as one. 12
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 47 references

Cited by

See all 14

Metadata

Authors
Scarborough, J. A., Eschrich, S. A., Torres-Roca, J., Dhawan, A., & Scott, J. G.
Affiliations
  • Cleveland Clinic (US)
  • Moffitt Cancer Center (US)
Corresponding author
  • Dhawan, Andrew
  • Scott, Jacob G.
Venue
npj Precision Oncology
Published
2023-04-19
Volume
7
Issue
1
Pages
38-38
ISSN
2397-768X (ISSN-L)
OpenAlex
W4366439897
Cited by
14
References
47
Citations by year
2026: 1 · 2025: 6 · 2024: 5 · 2023: 2
FWCI
1.24
Type
journal article
Language
en
Open access
Licence
Locations
  • npj Precision Oncology (publishedVersion, cc-by)
  • Research Square (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Foundation for the National Institutes of Health (5R37CA244613-02, 1F30CA257076, T32GM007250)
  • American Cancer Society (RSG-20-096-01)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
Keywords
cisplatin response, gene expression signatures, pan-cancer, chemotherapy response prediction, drug sensitivity, GDSC, TCGA, muscle-invasive bladder cancer, overall survival, precision oncology

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Exploiting convergent phenotypes to derive a pan-cancer cisplatin response gene expression signature. https://app.cochat.ai/papers/10.1038/s41698-023-00375-y
The paper
Scarborough, J. A., Eschrich, S. A., Torres-Roca, J., Dhawan, A., & Scott, J. G. (2023). Exploiting convergent phenotypes to derive a pan-cancer cisplatin response gene expression signature. npj Precision Oncology. https://doi.org/10.1038/s41698-023-00375-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.